The diabetic patient at altitude: Pathophysiology and practical implications;Le diabétique en altitude: Physiopathologie et conséquences pratiques

Revue Medicale Suisse

Volumn 3, Issue 114, 2007, Pages 1463-1468

  Thalmann, Sébastien ^a   Gojanovic, Boris ^b   Jornayvaz, François R ^a   Gremion, Gérald ^b   Philippe, Jacques ^a  

^a HUG   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALTITUDE; ALTITUDE DISEASE; ANOREXIA; DIABETES MELLITUS; FREEZING; HUMAN; HYPOGLYCEMIA; HYPOXIA; MOUNTAINEERING; PATIENT ATTITUDE; PREVALENCE; RECREATION; REVIEW;

ALTITUDE; DIABETES MELLITUS; HUMANS; MOUNTAINEERING;

EID: 34250898563     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. IDF. Prevalence of obesity. www.eatlas.idf.org/ Obesity_and_type_2_diabetes/Prevalence_of_obesity/
2. Wiedman M, Tabin GC. High-altitude retinopathy and altitude illness. Ophthalmology 1999;106:1924-6.
3. ** Brubaker PL. Adventure travel and type I diabetes: The complicating effects of high altitude. Diabetes care 2005;28:2563-72.
4. * Brion R. [The heart and the mountains]. Arch Mal Cœur Vaiss 2006;99:1121-5.
5. Scherrer U, Turini P, Thalmann S, et al. Pulmonary hypertension in high-altitude dwellers: Novel mechanisms, unsuspected predisposing factors. Adv Exp Med Biol 2006;588:277-91.
6. ** Hackett PH, Roach RC. High-altitude illness. N Engl J Med 2001;345:107-14.
7. Barnholt KE, Hoffman AR, Rock PB, et al. Endocrine responses to acute and chronic high-altitude exposure (4,300 meters): Modulating effects of caloric restriction. Am J Physiol Endocrinol Metab 2006;290:E1078-88.
8. * Larsen JJ, Hansen JM, Olsen NV, et al. The effect of altitude hypoxia on glucose homeostasis in men. J Physiol 1997;504 (Pt 1):241-9.
9. Tschop M, Strasburger CJ, Hartmann G, et al. Raised leptin concentrations at high altitude associated with loss of appetite. Lancet 1998;352:1119-20.
10. Roberts AC, Butterfield GE, Cymerman A, et al. Acclimatization to 4,300 m altitude decreases reliance on fat as a substrate. J Appl Physiol 1996;81:1762-71.
11. * Leal C. Going high with type I diabetes. High Alt Med Biol 2005;6:14-21.
12. Fleming DR, Jacober SJ, Vandenberg MA, et al. The safety of injecting insulin through clothing. Diabetes care 1997;20:244-7.
13. Moore K, Vizzard N, Coleman C, et al. Extreme altitude mountaineering and type I diabetes; the Diabetes federation of Ireland Kilimanjaro expedition. Diabet Med 2001;18:749-55.
14. Admetlla J, Leal C, Ricart A. Management of diabetes at high altitude. Br J Sports Med 2001;35:282-3.
15. * Maggiorini M, Brunner-La Rocca HP, Peth S, et al. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: A randomized trial. Ann Intern Med 2006;145:497-506.
16. Wyss CA, Koepfli P, Fretz G, et al. Influence of altitude exposure on coronary flow reserve. Circulation 2003;108:1202-7.
17. Schobersberger W, Schmid P, Lechleitner M, et al. Austrian moderate altitude study 2000 (AMAS 2000). The effects of moderate altitude (1,700 m) on cardiovascular and metabolic variables in patients with metabolic syndrome. Eur J Appl Physiol 2003;88:506-14.
18. Sayarlioglu H, Erkoc R, Dogan E, et al. Nephropathy and retinopathy in type 2 diabetic patients living at moderately high altitude and sea level. Ren Fail 2005;27:67-71.
19. Pavan P, Sarto P, Merlo L, et al. Metabolic and cardiovascular parameters in type I diabetes at extreme altitude. Med Sci Sports Exerc 2004;36:1283-9.
20. www.idea2000.org/
21. www.usd.asso.fr/
22. www.diabetes-sport.ch
23. www.runsweet.com